Cord Blood Banking for Potential Future Transplantation
- 1 January 2007
- journal article
- guideline
- Published by American Academy of Pediatrics (AAP) in PEDIATRICS
- Vol. 119 (1), 165-170
- https://doi.org/10.1542/peds.2006-2901
Abstract
In recent years, umbilical cord blood, which contains a rich source of hematopoietic stem and progenitor cells, has been used successfully as an alternative allogeneic donor source to treat a variety of pediatric genetic, hematologic, immunologic, and oncologic disorders. Because there is diminished risk of graft-versus-host disease after transplantation of cord stem cells using matched related donors, the use of less-than-completely matched HLA cord blood stem cells may incur less risk of graft-versus-host disease than mismatched cells from either a related or unrelated “walking” donor, although this remains to be proven. Gene-therapy research involving modification of autologous cord blood stem cells for the treatment of childhood genetic disorders, although experimental at the present time, may prove to be of value. These scientific advances have resulted in the establishment of not-for-profit and for-profit cord blood–banking programs for allogeneic and autologous cord blood transplantation. Many issues confront institutions that wish to establish or participate in such programs. Parents often seek information from their physicians about this new biotechnology option. This document is intended to provide information to guide physicians in responding to parents’ questions about cord blood donation and banking and the types and quality of cord blood banks. Provided also are recommendations about appropriate ethical and operational standards, including informed consent policies, financial disclosures, and conflict-of-interest policies for physicians, institutions, and organizations that operate or have a relationship with cord blood–banking programs.This publication has 60 references indexed in Scilit:
- Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia – the role of busulfan pharmacokinetics in determining outcomeBone Marrow Transplantation, 2005
- Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group reportLeukemia, 2005
- Allogeneic versus autologous versus peripheral stem cell transplantation in CR1 pediatric AML patients: A single center experiencePediatric Blood & Cancer, 2005
- Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimensTransplantation and Cellular Therapy, 2004
- A New Human Somatic Stem Cell from Placental Cord Blood with Intrinsic Pluripotent Differentiation PotentialThe Journal of Experimental Medicine, 2004
- Multilineage hematopoietic engraftment after allogeneic peripheral blood stem cell transplantation without conditioning in SCID patientsBone Marrow Transplantation, 2004
- Unrelated Umbilical Cord Blood Transplantation for an Infant With ??-Thalassemia MajorJournal of Pediatric Hematology/Oncology, 2004
- Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioningBlood, 2003
- Placental Blood as a Source of Hematopoietic Stem Cells for Transplantation into Unrelated RecipientsThe New England Journal of Medicine, 1996
- Hematopoietic Reconstitution in a Patient with Fanconi's Anemia by Means of Umbilical-Cord Blood from an HLA-Identical SiblingThe New England Journal of Medicine, 1989